Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

La Jolla Pharmaceutical Co

CIK: 920465 Ticker: LJPC
Exhibit 99.1



ljpcpressrelease_image1a23.jpg
La Jolla Pharmaceutical Company Announces Financial Results for the
Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives

SAN DIEGO, CA - March 4, 2019 - La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2018 and highlighted recent corporate progress and key objectives.

Recent Corporate Progress and Key Objectives

GIAPREZATM (angiotensin II)

2018 Net Sales: Fourth-quarter 2018 net sales were $4.2 million, up 20% from the third quarter of 2018. 2018 net sales were $10.1 million. GIAPREZA was launched in March 2018.

2019 Net Sales Guidance: La Jolla expects 2019 net sales of $24 million to $28 million.

Decision on GIAPREZA MAA by EMA Expected in June of 2019: La Jolla expects a decision on the GIAPREZA Marketing Authorisation Application (MAA) by the European Medicines Agency (EMA) in June of 2019.

Investigational Products Update

NDA Planned for New Investigational Product, LJPC-0118, for the Treatment of Severe Malaria, in Fourth Quarter of 2019: La Jolla plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2019 for LJPC-0118. LJPC-0118 is La Jolla’s new investigational product for the treatment of severe malaria. The active pharmaceutical ingredient in LJPC-0118 was demonstrated to be superior to quinine in reducing mortality in patients with severe falciparum malaria infection in two randomized, controlled, clinical studies.

Topline Results of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis Expected in Second Half of 2019: La Jolla expects topline results in the second half of 2019 for LJ401-HH01, a multinational, multicenter, randomized, Phase 2 study that is designed to evaluate the safety and efficacy of LJPC-401, La Jolla’s proprietary formulation of synthetic human hepcidin, as a treatment for hereditary hemochromatosis (HH). The primary efficacy endpoint of the study is the change in transferrin saturation, a standard measurement of iron levels in the body and one of the two key measurements used to detect iron overload, from baseline to end of treatment.     

Topline Results of Pivotal Study of LJPC-401 in Patients with Beta Thalassemia Expected in Mid-2020: La Jolla expects topline results in mid-2020 for LJ401-BT01, a pivotal, multinational, multicenter, randomized, controlled study that is designed to evaluate the safety and efficacy of LJPC-401 as a treatment for beta thalassemia (BT) patients who, despite chelation therapy, have cardiac iron levels above normal. The primary efficacy endpoint of this study is the change in iron content in the heart after 6 months, as measured by cardiac magnetic resonance imaging (MRI). If this study is successful, La Jolla anticipates filing an MAA for LJPC-401 in the European Union (EU).


“We are excited to have launched GIAPREZA, our first commercial product, in 2018, and we look forward to executing on a number of initiatives that we believe will support its continued, increased adoption in 2019,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “Our two randomized studies of LJPC-401 in BT and HH have the potential to demonstrate improved patient outcomes in these important diseases. Furthermore, we are excited to have recently announced a planned NDA submission for LJPC-0118, our new investigational product for the treatment of severe malaria, in the fourth quarter of 2019.”



The following information was filed by La Jolla Pharmaceutical Co (LJPC) on Monday, March 4, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Other
Filter by Subcategory:
All
Expense
Other
Inside La Jolla Pharmaceutical Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Unaudited Condensed Consolidated Statements Of Cash Flows
Unaudited Condensed Consolidated Statements Of Operations
Unaudited Consolidated Statements Of Shareholders' Equity
Balance Sheet Account Details
Balance Sheet Account Details (Narrative) (Details)
Balance Sheet Account Details (Summary Of Accrued Expenses) (Details)
Balance Sheet Account Details (Schedule Of Inventory) (Details)
Balance Sheet Account Details (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Narrative) (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Schedule Of Concentration Risk) (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Business
Business (Narrative) (Details)
Company-Wide Realignment (Notes)
Deferred Royalty Obligation
Deferred Royalty Obligation (Details)
Equity Incentive Plans
Equity Incentive Plans (Narrative) (Details)
Equity Incentive Plans (Share-Based Compensation Expense) (Details)
Equity Incentive Plans (Stock Option Activity) (Details)
Equity Incentive Plans Equity Incentive Plan (Tables)
Leases (Lease Liability Maturity) (Details)
Leases (Narrative) (Details)
Leases (Tables)
Leases Leases
Restructuring (Details)
Stockholders' Equity (Details)
Stockholders' Equity Stockholders' Equity

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Ticker: LJPC
CIK: 920465
Form Type: 10-Q Quarterly Report
Accession Number: 0000920465-19-000077
Submitted to the SEC: Mon May 06 2019 12:03:35 PM EST
Accepted by the SEC: Mon May 06 2019
Period: Sunday, March 31, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0000920465-19-000077.htm